Research Progress on CDK4/6 Inhibitors Combined with Endocrine Therapy for Advanced Breast Cancer
DOI:
https://doi.org/10.53469/jcmp.2024.06(12).27Keywords:
Breast cancer, CDK4/6 inhibitors, Endocrine therapy, EfficacyAbstract
The introduction of CDK4/6 inhibitors has revolutionized the treatment paradigm for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. These inhibitors, when combined with endocrine therapy, have shown significant improvements in both progression-free survival (PFS) and overall survival (OS). However, the development of resistance presents substantial challenges that limit their long-term effectiveness. This article provides a review of the mechanisms of action, clinical efficacy, and safety of CDK4/6 inhibitors, as well as treatment after disease progression on a CDK4/6 inhibitor, offering valuable references.
References
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263.
RUGO H S, RUMBLE R B, MACRAE E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline [J]. J Clin Oncol, 2016, 34(25): 3069-3103.
OSBORNE C K, SCHIFF R. Mechanisms of endocrine resistance in breast cancer [J]. Annu Rev Med, 2011, 62: 233-247.
MURPHY C G. The Role of CDK4/6 Inhibitors in Breast Cancer [J]. Curr Treat Options Oncol, 2019, 20(6): 52.
ASGHAR U, WITKIEWICZ A K, TURNER N C, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy [J]. Nat Rev Drug Discov, 2015, 14(2): 130-146.
GOEL S, DECRISTO M J, MCALLISTER S S, et al. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest [J]. Trends Cell Biol, 2018, 28(11): 911-925.
KLEIN M E, KOVATCHEVA M, DAVIS L E, et al. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought [J]. Cancer Cell, 2018, 34(1): 9-20.
GOEL S, DECRISTO M J, WATT A C, et al. CDK4/6 inhibition triggers anti-tumour immunity [J]. Nature, 2017, 548(7668): 471-475.
WATT A C, GOEL S. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer [J]. Breast Cancer Res, 2022, 24(1): 17.
WEKKING D, LEONI V P, LAMBERTINI M, et al. CDK4/6 inhibition in hormone receptor-positive / HER2-negative breast cancer: Biological and clinical aspects [J]. Cytokine Growth Factor Rev, 2024, 75: 57-64.
RUGO H S, FINN R S, DIéRAS V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up [J]. Breast Cancer Res Treat, 2019, 174(3): 719-729.
SLAMON D J, DIéRAS V, RUGO H S, et al. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer [J]. J Clin Oncol, 2024, 42(9): 994-1000.
CRISTOFANILLI M, RUGO H S, IM S A, et al. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study [J]. Clin Cancer Res, 2022, 28(16): 3433-3442.
HORTOBAGYI G N, STEMMER S M, BURRIS H A, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer [J]. Ann Oncol, 2018, 29(7): 1541-1547.
HORTOBAGYI G N, STEMMER S M, BURRIS H A, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer [J]. N Engl J Med, 2022, 386(10): 942-950.
SLAMON D J, NEVEN P, CHIA S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer [J]. N Engl J Med, 2020, 382(6): 514-524.
NEVEN P, FASCHING P A, CHIA S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant [J]. Breast Cancer Res, 2023, 25(1): 103.
SLEDGE G W, JR., TOI M, NEVEN P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial [J]. JAMA Oncol, 2020, 6(1): 116-124.
GOETZ M P, TOI M, HUOBER J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3 [J]. Ann Oncol, 2024, 35(8): 718-727.
ZHANG P, ZHANG Q, TONG Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2023, 24(6): 646-657.
XU B, ZHANG Q, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial [J]. Nat Med, 2021, 27(11): 1904-1909.
KALINSKY K, ACCORDINO M K, CHIUZAN C, et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial [J]. J Clin Oncol, 2023, 41(24): 4004-4013.
BIDARD F C, HARDY-BESSARD A C, DALENC F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial [J]. Lancet Oncol, 2022, 23(11): 1367-1377.
BIHANI T, PATEL H K, ARLT H, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER(+) Breast Cancer Patient-derived Xenograft Models [J]. Clin Cancer Res, 2017, 23(16): 4793-4804.
BIDARD F C, KAKLAMANI V G, NEVEN P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial [J]. J Clin Oncol, 2022, 40(28): 3246-3256.
TURNER N C, OLIVEIRA M, HOWELL S J, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer [J]. N Engl J Med, 2023, 388(22): 2058-2070.
ANDRé F, CIRUELOS E, RUBOVSZKY G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J]. N Engl J Med, 2019, 380(20): 1929-1940.
JACOBSON A. Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer [J]. Oncologist, 2022, 27(Suppl 1): S13-s14.
BARDIA A, HURVITZ S A, DEMICHELE A, et al. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1) [J]. Clin Cancer Res, 2021, 27(15): 4177-4185.
JIANG Z, LI W, HU X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol, 2019, 20(6): 806-815.
KOLYADINA I V, BOLOTINA L, ZHUKOVA L, et al. The effectiveness and safety of eribulin therapy in HR-positive HER2-negative metastatic breast cancer post-CDK4/6 inhibitor therapy in Russian clinical practice [J]. Journal of Clinical Oncology, 2021, 39(15_suppl): e13035-e13035.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Qingfeng Wu, Lishan Xu, Lu Gan
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
